dropless cataract surgery

NSAID after Dropless approach shown to lower CMEThere was clinically significant less CME in patients who received trans-zonular triamcinolone acetonide, moxifloxacin hydrochloride, and vancomycin—known as the Dropless approach—in addition to an NSAID after cataract surgery.
Intracanalicular drug depot may fill unmet need for better topical therapyA sustained-release dexamethasone intracanalicular depot may be able to treat post-cataract surgery inflammation without causing spikes in IOP. The product’s one-time administration may also improve compliance and convenience.
Scientific evidence mounting for superior outcomes with dropless cataract surgeryKevin M. Barber, MD, explains how a dropless cataract surgery approach helps to alleviates anxiety, cost burdens, and adherence issues associated with traditional drop therapy.
The effect of drug pricing on cataract surgeryIn a recent wave of drug price increases that can only be explained by pharmaceutical manufacturers’ desire for profit maximization and which doctors and patients may call price gouging, the drug price war has been brought to the doorsteps of many eyecare providers. As optometrists are increasing their practice of medical optometry, patients are now calling their doctors about prior authorizations and unaffordable drug copays.
Drug therapies improving refractive outcomesLines continue to blur as to what constitutes refractive surgery, and likely will continue to blur well into the future. Multiple compounds—phenylephrine and ketorolac 1%/0.3%, (Omidria, Omeros) and the “Dropless” line (Tri-Moxi/Tri-moxi-Vanc, Imprimis Pharmaceuticals)—are designed for use in cataract surgery, but their goal is to improve refractive outcomes. 2015 was the year they started to get some serious attention.
Intraocular medications gaining traction in cataract proceduresAlthough no new drug therapies entered cataract surgeons’ armamentarium in 2015, interest continues to grow in approaches for intraocular administration.
Dropless cataract surgery yields postoperative prophylaxis for patients, practicesDropless cataract surgery—a combination of anti-infective and anti-inflammatory drugs injected transzonularly or through the pars plana for deposit into the vitreous—reduces the need for topical postoperative drops.
Dropless cataract surgery offers ‘significant benefit’Examining how utilizing an intravitreal transzonular injection can help patient compliance.